New Delivery Methods Boost CRISPR Gene Editing Efficiency Up to 90 Percent

Scientists have unveiled two distinct breakthrough strategies to dramatically enhance the efficacy of gene editing and mRNA therapies, addressing a persistent challenge that has limited the translation of laboratory success into clinical applications.

Researchers at Biohub discovered that co-administration of three amino acids—methionine, arginine, and serine—can amplify therapeutic payload delivery by up to 20-fold and elevate CRISPR gene editing efficiencies from a modest 25 percent to nearly 90 percent in vivo. The discovery marks a watershed moment for molecular medicine, as lipid nanoparticles have long faced challenges in translating their spectacular laboratory performance into equivalent success within living organisms.

The Biohub team, led by Dr. Daniel Zongjie Wang and Dr. Shana O. Kelley, reframed the problem by looking beyond the nanoparticles themselves and focusing instead on the cellular environment and metabolic state that regulate membrane interactions. When the researchers modeled a more authentic physiological environment using a human plasma–like medium, LNP uptake by cells decreased precipitously. Further metabolic and genetic analyses pinpointed attenuated amino acid-related pathways as a critical bottleneck.

The optimized cocktail, comprised solely of pharmaceutical-grade methionine, arginine, and serine—three amino acids ubiquitously available and considered safe for clinical use—proved transformative. The amino acid supplement dramatically enhanced the uptake and functional expression of mRNA cargo across diverse cell types. This effect was consistent regardless of the route of administration, whether intramuscular, intratracheal, or intravenous, and was agnostic to the nanoparticle lipid composition or the nature of the genetic cargo.

Mechanistically, co-delivery of the amino acid supplement appears to modulate a specific cellular uptake pathway, effectively widening the cellular "doorway" through which lipid nanoparticles gain entry. By energizing amino acid metabolic circuits, the cells are metabolically primed to more efficiently internalize nanocarriers and unleash their therapeutic payloads.

In a preclinical mouse model of acetaminophen-induced acute liver failure, the addition of the amino acid supplement converted a perilously low 33 percent survival rate into complete survival following treatment with growth hormone mRNA encapsulated in LNPs. This remarkable improvement was accompanied by a nearly ninefold surge in serum therapeutic protein levels and normalization of liver damage and inflammatory markers to near-healthy baselines. In gene editing applications targeting pulmonary tissue, the supplement catapulted CRISPR-Cas9 editing efficiency from the typical 20 to 30 percent range to an unprecedented 85 to 90 percent with just a single dose.

Separately, a team at the University of California, Berkeley led by gene-editing pioneer and Nobel Prize winner Jennifer Doudna developed a self-replicating CRISPR system that spreads between cells like a virus. The scientists added genetic instructions for cells to make a virus-like transporter that can encapsulate the CRISPR machinery. Once manufactured in treated cells, the CRISPR cargo ships to neighboring cells.

The system, called NANoparticle-Induced Transfer of Enzyme, or NANITE, combines genetic instructions for the carrier molecules and CRISPR machinery into a single circular piece of DNA. This ensures the Cas9 enzyme is physically linked to the delivery proteins as both are being made inside a cell. It also means the final delivery vehicle encapsulates guide RNA as well, the "bloodhound" that tethers Cas9 to its DNA target.

Like a benevolent virus, NANITE initially "infects" a small number of cells. Once inside, it instructs each cell to make the full CRISPR tool, package it up, and send it along to other cells. The upgraded editor was roughly three times more effective at gene editing lab-grown cells compared to standard CRISPR. It also lowered the amount of a harmful protein in mice with a genetic metabolic disorder, while the original version had little effect at the same dose.

Gene editors promise to revolutionize medicine by overriding or correcting the underlying genetic basis of disease, but all these tools are throttled by one basic requirement: Enough cells have to be edited that they override their diseased counterparts. Treatments need to correct around 20 percent of blood stem cells to keep sickle cell disease at bay. For Duchenne muscular dystrophy, an inherited disease that weakens muscles, over 15 percent of targeted cells need to be edited.

Once delivered to cells, editing machinery is confined to the cells it initially enters. To compensate, scientists often increase the dosage, but this risks triggering immune attacks and off-target genetic edits. Both new approaches offer potential solutions to this fundamental limitation in gene therapy delivery.